High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial [Hematologic Malignancy]

Conclusion
The combination of high doses of antimetabolites, R-HDS, and ASCT is feasible and effective in patients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therapeutic option.

Source: Journal of Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Authors: Ferreri, Donadoni, Cabras, Patti, Mian, Zambello, Tarella, Di Nicola, D'Arco, Doa, Bruno-Ventre, Assanelli, Foppoli, Citterio, Fanni, Mule, Caligaris-Cappio, Ciceri Tags: Lymphoma, Chemotherapy Hematologic Malignancy Source Type: research